Related Experiment Video
Updated: Jun 22, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
[Clinical evaluation of CNS drugs with PET]
1Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, S-171 76 Stockholm, Sweden. Akihiro.Takano@ki.se
Abstract:
The utility and possibility of PET in the drug development of the neuropsychiatry field is discussed in this review. Positron emission tomography (PET) is a nuclear medicine imaging technique which visualizes and quantifies the distributions of various molecular targets in vivo. This technique has been expected to help the process to be more efficient in the drug development of the neuropsychiatry field. Three approaches have been raised as promising ways: microdosing, occupancy measurement at the target region, and biomarkers. In microdosing, it could be detected whether the drugs enter the living human brain or not using very small amount of radiolabelled candidate drugs. With occupancy measurement, the relationship between the dose of the drug and the occupancy could be established, and the optimal clinical doses could be obtained. As biomarkers, the change in the distribution in beta amyloid and microglia after the drug treatment could be detected.
More Related Videos
11:51Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
Published on: August 16, 2010
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
Related Concept Videos
Factors Affecting Drug Response: Overview
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists